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PURPOSE. The purpose of this study was to evaluate the effect of disease severity and number
of tests acquired during follow-up on the relative odds of identifying progression by structural
or functional tests in glaucoma.
METHODS. This was an observational cohort study involving 462 eyes of 305 patients with
glaucoma and 62 eyes of 49 healthy subjects. Glaucoma patients and healthy subjects were
followed for an average of 3.6 6 0.9 and 3.8 6 0.9 years, with a median (interquantile range)
of 8 (6–9) and 7 (6–8) visits, respectively. At each visit, subjects underwent visual field
assessment with standard automated perimetry (SAP) and retinal nerve fiber layer (RNFL)
evaluation by spectral-domain optical coherence tomography (SD-OCT). Slopes of change in
SAP mean sensitivity and OCT RNFL thickness over time were estimated by linear regression
using progressively cumulative visits over time. Cutoff values for age-related expected rates of
change for each test were obtained from the healthy group. Progression by SD-OCT and/or
SAP was determined if the slope of change was statistically significant and also lower (faster)
than the fifth percentile cutoff calculated from the healthy group. A generalized estimating
equation logistic regression model was used to evaluate the relative odds of progressing by
OCT versus SAP in glaucoma eyes.
RESULTS. Eyes with less severe disease at baseline had a higher chance of being detected as
progressing by SD-OCT but not by SAP, whereas an increase in disease severity at baseline
increased the chance that the eye would be detected as progressing by SAP but not SD-OCT.
Each 1 dB higher MD was associated with a 5% increase in the odds of detecting progression
by SD-OCT versus SAP (odds ratio ¼ 1.05 per 1 dB; 95% confidence interval: 1.01–1.09; P ¼
0.005).
CONCLUSIONS. The ability to detect glaucoma progression by SAP versus SD-OCT is significantly
influenced by the stage of disease. Our results may provide useful information for guiding
clinicians on the relative utility of these tests for detecting change throughout the disease
continuum.
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Glaucoma is a progressive optic neuropathy associated withloss of retinal ganglion cells, leading to characteristic optic
nerve and retinal nerve fiber layer (RNFL) changes and loss of
visual function.1 Reduction of intraocular pressure has been
shown to halt or slow down the rate of deterioration; therefore,
detection of progressive damage is essential in management
decisions about when to initiate or advance therapy, as well as
in determining response to treatment.2,3
Despite its fundamental importance in the management of
the disease, there is no consensus with regard to the best
method for detecting progression and measuring rates of
change in glaucoma. Although standard automated perimetry
(SAP) is the most widely used method for assessing functional
loss, many patients can show progressive structural changes to
the optic disc and RNFL despite the absence of detectable
changes on standard perimetry. These structural losses are
usually quantified by imaging technologies, such as confocal
scanning laser ophthalmoscopy, scanning laser polarimetry, or
optical coherence tomography (OCT).3–5 Structural changes
have been shown to be predictive of future functional losses
and to be associated with a decrease in quality of life, carrying
important prognostic significance for the patient.6,7 However, a
large proportion of patients with glaucoma may also show
progressive functional loss on SAP in the absence of detectable
structural change.8 Although several studies have attempted to
clarify the reasons for this apparent disagreement, it is still
unclear in what circumstances detection of progression is
facilitated by one or the other method.
The ability of a specific test to detect glaucomatous
progression may depend on several factors, such as stage of
the disease, test–retest variability, and number or frequency of
tests acquired during follow-up.9,10 Previous studies have
suggested that structural tests may perform better for detecting
progression at earlier stages of damage, whereas functional
ones may perform better at later stages.11 However, the
relationship between stage of disease and ability to detect
progression has not been well characterized and quantified in
the literature. In addition, the influence of number of tests
acquired during follow-up on the relative ability to detect
progression by different structural and functional tests has not
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been reported. Although increasing the number of tests will
generally lead to higher chances of detecting progressive
damage, the increase in the probability of detecting progres-
sion may be different according to the type of test being using
and the stage of the disease.12 These are important consider-
ations as an understanding and quantification of such
relationships may provide a better allocation of resources by
allowing clinicians to tailor the frequency of testing by one or
the other method according to the stage of disease and the
expected probability that the test will be able to detect
progressive damage. Such a strategy could help maximize the
chances of detecting progression while minimizing the costs
associated with repeated testing.
In the current study, we evaluated the influence of factors
such as stage of disease and number of tests on the relative ability
of SAP and spectral-domain (SD)-OCT in detecting progression in
a cohort of glaucoma patients followed over time.
METHODS
This was an observational study. Participants from this study
were included in a prospective longitudinal study designed to
evaluate optic nerve structure and visual function in glaucoma
(the Diagnostic Innovations in Glaucoma Study) conducted at
the Hamilton Glaucoma Center at the Department of Ophthal-
mology, University of California, San Diego (UCSD). The
institutional review board approved the study methodology,
which adhered to the tenets of the Declaration of Helsinki and
to the Health Insurance Portability and Accountability Act.
At each visit during follow-up, patients underwent a
comprehensive ophthalmologic examination including review
of medical history, best-corrected visual acuity, slit-lamp
biomicroscopy, intraocular pressure, gonioscopy, dilated oph-
thalmoscopic examination, stereoscopic optic disc photograph
(Kowa Nonmyd WX3D; Kowa Optimed, Inc., Torrance, CA,
USA), SD-OCT testing (Spectralis; Heidelberg Engineering,
Dossenheim, Germany), and SAP using the Swedish interactive
threshold algorithm (SITA standard 24-2; Carl Zeiss Meditec,
Inc., Dublin, CA, USA). Subjects were excluded if they had any
ocular or systemic disease that could affect the optic nerve or
the visual field.
All patients had a diagnosis of glaucoma at baseline, based
on the presence of repeatable visual field defects on SAP and/
or glaucomatous optic neuropathy on optic disc stereophoto-
graphs. Repeatable visual field defects on SAP were defined as
at least three consecutive abnormal SAP results with pattern
standard deviation (PSD) with P < 0.05, and/or glaucoma
hemifield test results outside normal limits. Glaucomatous
optic neuropathy was evaluated by masked assessment of
stereophotographs and defined based on the presence of
neuroretinal rim thinning, excavation, notching, or character-
istic RNFL defects.13 Healthy subjects were recruited from the
general population through advertisements or from the staff
and employees at the UCSD. Healthy subjects had intraocular
pressures less than 22 mm Hg with no history of increased
intraocular pressure and at least two reliable normal visual
fields in both eyes, which were defined as a pattern SD within
95% confidence limits and a glaucoma hemifield test result
within normal limits. For inclusion in the analysis, each
glaucoma patient or healthy subject was required to have at
least five visits (with five SAP tests and five OCT tests) over a
follow-up duration of at least 2 years.
Optical Coherence Tomography
The Spectralis SD-OCT (software version 5.4.7.0) was used to
measure peripapillary RNFL thickness in the present study. The
device has been described in detail previously.14,15 All images
were reviewed by the UCSD Imaging Data Evaluation and
Analysis Center to ensure that the scan was centered, the signal
strength was more than 15 dB, that there were no artifacts, and
that there were no RNFL segmentation algorithm errors. The
OCT parameter used in the study was the global RNFL
thickness corresponding to the average of all RNFL thickness
measurements acquired from a 3.45-mm circle centered on the
optic disc consisting of 1536 A-scan points.
Standard Automated Perimetry
Visual fields were performed using SAP SITA 24-2 and evaluated
by the UCSD Visual Field Assessment Center (VisFACT).13
Visual fields were excluded if they had more than 33% fixation
losses or more than 15% false-positive errors. Visual fields were
excluded in the presence of the following artifacts: eyelid, rim
artifacts, fatigue effects, inappropriate fixation, or evidence
that the visual field results were caused by a disease other than
glaucoma or inattention. Visual fields exhibiting a learning
effect (i.e., initial tests showing consistent improvement on
visual field indices) were also excluded. The mean sensitivity
(MS) in decibels of each eye was calculated by converting each
threshold point into a linear scale (apostilbs) and then
averaging all 52 threshold points.16 The final value was then
converted back to logarithmic scale (decibels).
Data Analysis
Global parameters of structural and functional damage were
selected for evaluation in this study to provide a fair
comparison between the different tests. As comparable
localized parameters would be difficult to establish for SAP
and OCT, we restrained our analyses to global structural loss as
measured by the OCT RNFL average thickness and global
functional loss as measured by SAP MS. We used MS instead of
mean deviation (MD), as MD is an age-corrected parameter,
whereas global RNFL thickness and MS are not.
A challenge in evaluating the relative ability of different tests
in detecting glaucoma progression resides in equating their
specificities, so that sensitivities can be meaningfully com-
pared. When evaluating progression based on slopes of
change, the specificity can be set by the type I error. A
statistically significant slope at P < 0.05 implies that in only 5%
of the cases the slope would be declared statistically
significantly different from zero in cases where no change
truly existed. However, such approach may be insufficient to
establish specificity due to possible changes over time that can
occur from aging, instead of glaucoma progression. Therefore,
to take into account possible age effects, we established
confidence limits for the rates of change of OCT average RNFL
thickness and SAP MS using longitudinal data available from
healthy eyes. Slopes of change were obtained using linear
mixed models and cutoffs corresponding to the fifth percentile
of rates of change in the healthy group were obtained for each
parameter.17 It is expected that 95% of healthy eyes will have
rates of change slower (i.e., more positive) than the cutoff
value. After cutoffs were obtained from the healthy group,
individual slopes were calculated for each glaucoma eye and
for each test using ordinary least squares regression. Progres-
sion was then determined to have occurred if the slope was
statistically significant at P < 0.05 and also faster (i.e., more
negative) than the fifth percentile cutoff calculated from the
healthy group. This approach equated the specificities of the
tests by requiring statistically significant slopes at the same
type I error and also by taking into account age-related changes
by establishing confidence limits from the healthy group.
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For each glaucoma eye, slopes of change for each test were
calculated using progressively cumulative visits over time, with
a minimum of five visits. For example, for an eye that had a
total of 10 visits during follow-up, slopes of change were
calculated from data including only the first 5 visits, as well as
from the data including the first 6 visits, first 7 visits, and so on,
up to 10 visits. Therefore, for an eye with 10 visits during
follow-up, six slopes were calculated for each test. Progression
(yes/no) was then determined based on the criteria set on the
previous paragraph for each one of these slopes.
After progression (yes/no) was determined at each visit, a
logistic regression model was used to evaluate the relative odds
of progressing by OCT and SAP in the population.18 For the
logistic regression, eyes that progressed exclusively by OCT
were assigned the value 1, whereas eyes that progressed
exclusively by SAP were assigned the value 0. As we were
interested in evaluating the factors associated with progressing
by one method versus the other, eyes that progressed by both
methods or by none were excluded. As each eye could have
had multiple slopes for each test depending on the number of
visits during follow-up, each eye had a combination of 1s and
0s during follow-up, depending on whether progression was
detected solely by OCT or by SAP at each point during follow-
up. A generalized estimating equation (GEE) model was used to
deal with correlated observations from each eye.19 The GEE
logistic model evaluated the effect of the number of tests
during follow-up and disease severity at baseline on the relative
odds of progressing by OCT versus SAP. Baseline disease
severity was classified according to SAP MD in early (>6 dB),
moderate (<6 and >12 dB), and advanced (<12 dB).
Statistical analyses were performed using commercially
available software Stata, version 13 (StataCorp LP, College
Station, TX, USA). The a level (type I error) was set at 0.05.
RESULTS
The study included 462 eyes of 305 glaucoma patients and 62
eyes of 49 healthy controls. Table 1 shows the baseline clinical
and demographic characteristics of the subjects included in the
study. Glaucoma patients had a median of 8 visits (range, 5–18)
during an average follow-up of 3.6 6 0.9 years. For healthy
subjects, the median number of visits was 7 (range, 5–10), over
an average follow-up period of 3.8 6 0.9 years. Mean age at
baseline was 70.0 6 8.2 years in the glaucoma group and 69.1
6 8.5 years in the healthy group (P¼ 0.470). Average SAP MD
was4.8 6 5.9 and 0.0 6 1.2 dB, and global RNFL thickness at
baseline was 78.4 6 17.6 and 94.9 6 11.0 lm, in glaucoma
and healthy subjects, respectively.
As the number of visits for glaucoma eyes ranged from 5 to
18 visits, the number of slopes ranged from 1 to 14 for each
eye. There were in total 1910 slopes for all the glaucomatous
eyes included in the study. The fifth percentile cutoff values for
rates of change estimated from the healthy group were 0.35
dB/y for SAP MS and 1.48 lm/y for global RNFL thickness.
Progression was determined for each eye and each test if the
slope was faster than these cutoff values and also if the slope
was statistically significant at P < 0.05. From the 1910 slopes,
progression was detected solely by OCT in 363 slopes (19.0%),
solely by SAP in 183 slopes (9.5%), and by both OCT and SAP in
80 slopes (4.1%). Progression was not detected in 1284 slopes
(67.2%). As we were interested in factors explaining the
relative odds of progressing by one test versus the other,
subsequent analyses were conducted with the 546 slopes that
showed progression exclusively by OCT or exclusively by SAP.
Table 2 shows results of progression by OCT versus SAP
according to the number of visits and baseline disease severity.
The raw data suggested that OCT was able to detect more eyes
as progressing in comparison to SAP, except for eyes with
TABLE 1. Baseline Clinical and Demographic Characteristics of Healthy Subjects and Glaucoma Patients Included in the Study
Characteristics Healthy (N ¼ 62 Eyes, 49 Subjects) Glaucoma (N ¼ 462 Eyes, 305 Patients) P Value
Age, y 69.1 6 8.5 70.0 6 8.2 0.470
Sex, % female 62.7% 51.0% 0.147
Median number of visits (IQR) 7 (6–8) 8 (6–9) 0.209
Follow-up, y 3.8 6 0.9 3.6 6 0.9 0.389
Baseline RNFL thickness, lm 94.9 6 11.0 78.4 6 17.6 <0.001
Baseline SAP MD, dB 0.0 6 1.2 4.8 6 5.9 <0.001
IQR, interquantile range.
TABLE 2. Total Number of Visits With Progression Detected by SAP and SD-OCT, According to Baseline Disease Severity and the Number of Visits
During Follow-Up
Number of Visits Early Moderate Advanced Total
Less than 8 visits
Progression by SAP 67 (29%) 13 (28%) 6 (35%) 86 (29%)
Progression by SD-OCT 162 (71%) 34 (72%) 11 (65%) 207 (71%)
Total 229 47 17 293
Between 8 and 12 visits
Progression by SAP 40 (31%) 20 (61%) 1 (14%) 61 (36%)
Progression by SD-OCT 91 (69%) 13 (39%) 6 (86%) 110 (64%)
Total 131 33 7 171
More than 12 visits
Progression by SAP 22 (37%) 12 (60%) 2 (100%) 36 (44%)
Progression by SD-OCT 38 (63%) 8 (40%) 0 (0%) 46 (56%)
Total 60 20 2 82
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moderate and severe disease and when a large number of tests
were available (Fig. 1).
This was confirmed by the results of the GEE logistic model,
as shown in Table 3. Each 1 dB higher MD was associated with
a 5% increase in the odds of detecting progression by OCT
versus SAP (odds ratio [OR] ¼ 1.05 per 1 dB; 95% confidence
interval [CI]: 1.01–1.09; P ¼ 0.005). That is, eyes with less
severe disease at baseline had higher chance of being detected
as progressing by OCT but not by SAP, whereas an increase in
disease severity at baseline increased the chance that the eye
would be detected as progressing by SAP but not OCT. A
higher number of visits during follow-up was associated with a
decrease in the relative odds of progressing by OCT versus SAP
(OR¼ 0.86 per visit; 95% CI: 0.81–0.93; P < 0.001). Although
an increase in the number of visits would be expected to
increase the chance of detecting progression by both OCT and
SAP, it is important to keep in mind that the model evaluated
the odds of progressing by one test versus the other. The
results show that for eyes with few visits during follow-up,
OCT had a higher chance of detecting progression compared
with SAP. Importantly, there was also a significant interaction
between baseline disease severity and number of visits in
explaining the relative odds of progressing by OCT versus SAP.
For eyes with early disease and relatively small number of visits,
the odds of detecting progression by OCT were in general
much larger for OCT compared with SAP (Fig. 1). Conversely,
for eyes with advanced disease and relatively large number of
visits available during follow-up, the odds of detecting
progression by SAP were greater than by OCT. Figures 2 and
3 show cases of eyes included in the study illustrating
differences in the ability to detect progression by OCT and SAP.
DISCUSSION
The present study demonstrated that the relative odds of
identifying progression by structural or functional tests varies
according to the number of tests performed during the follow-
up and also according to the disease severity at baseline. These
findings may have significant implications for the evaluation of
glaucoma progression in clinical practice by allowing clinicians
to tailor the frequency of SAP and OCT tests during follow-up,
taking into account the relative odds of detecting progression
at different levels of disease severity.
Several studies have previously shown substantial disagree-
ment when evaluating detection of glaucoma progression by
structural and functional tests.8,11,20–24 Our results agree with
this observation. From the 626 slopes showing progression,
progression was detected simultaneously by SAP and SD-OCT
in only 80 (13%) of them. In the vast majority of cases,
progression was either shown by SD-OCT or by SAP, but not by
both. Therefore, we built a model evaluating the relative odds
of progression by SD-OCT versus SAP in an attempt to
understand factors that could explain why some eyes are
detected as changing by one test but not by the other. The
model showed that in eyes with less severe disease at baseline
the odds of detecting progression by SD-OCT were generally
higher than the odds of detecting change by SAP. Each 1 dB
higher baseline MD was associated with a 5% increase in the
odds of progression being detected by SD-OCT versus SAP. This
can be clearly seen on Figure 1. When slopes were calculated
from eight visits, the probability of detecting progression by
SD-OCT when the baseline MD was 1 dB, for example, was
70% compared to only 30% for SAP. Equal probabilities (i.e.,
50% each) for detecting progression for SAP and SD-OCT would
occur for a baseline MD of10 dB. For eyes with baseline MD
worse than10 dB, the probability of detecting progression by
SAP would be larger than by SD-OCT considering slopes
calculated from eight visits. For example, for a baseline MD of
20 dB, the estimated probability of detecting progression by
SAP was 70% versus only 30% for SD-OCT. These results are in
agreement with previous suggestions in the literature that
structural assessment by SD-OCT would perform better for
detection of disease progression in early stages of damage,
whereas SAP would perform better for more advanced
cases.11,21,25 However, to the best of our knowledge, no
previous study has provided a quantification of the impact of
disease severity on the relative odds of detecting change by
these two methods.
The relationship between ability to detect change and
disease severity may be explained by a number of factors.
Previous studies investigating the structure and function
relationship in glaucoma have shown that when measurements
are expressed in their original scales (i.e., dB for SAP and lm
for RNFL), a nonlinear relationship is seen.11,26–31 From this
nonlinear relationship, it can be extracted that for eyes at
relatively early stages of damage, substantial change in RNFL
measurements might be seen when only relatively small
changes in visual function are seen in decibels. In contrast,
for eyes at advanced stages of disease, even relatively small
neural losses will produce large changes in the decibel scale. It
is important to note that the nonlinear relationship between
structure and function seems to be mostly the result of the
logarithmic scaling of visual field data, as transformation of
functional data to a linear scale (or structural data to a decibel
scale) seems to produce a closely linear relationship between
functional and structural measurements.11,28,32 However, such
post hoc transformations will not influence the ability of a test
to detect change as long as the original measurements are still
acquired in a decibel scale (i.e., the staircase procedures for
threshold acquisition still acquired on decibel steps). Another
FIGURE 1. Estimated probabilities of detecting progression by SD-OCT
versus SAP, according to different levels of disease severity at baseline
and number of tests acquired during follow-up.
TABLE 3. Logistic GEE Model Evaluating Factors Explaining the
Relative Odds of Progressing by OCT Versus SAP
Parameter OR P Value 95% CI
Baseline MD (per 1 dB higher) 1.05 0.005 1.01–1.09
Number of visits (per visit) 0.86 <0.001 0.81–0.93
Baseline MD 3 number of visits 1.02 0.005 1.01–1.04
Age at baseline 0.95 <0.001 0.93–0.98
Baseline MD was centered on the mean of glaucoma group (4.80
dB). Number of visits was centered on the mean of glaucoma group
(7.5). Age was centered on the mean of glaucoma group (70.0).
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factor influencing the relative ability of structural and
functional tests in detecting progression is the presence of
floor effects. For SD-OCT average RNFL thickness measure-
ments, a floor effect seems to occur when measurements are
close to 50 lm, although there are variations according to
specific instruments.33–36 When the floor is reached, even
further neural losses will go relatively undetected by RNFL
thickness measurements. The presence of such floor has been
shown by several previous investigations and seems to be
related to the presence of nonneural or glial tissue, as well as to
the dynamic range of the instrument.36
Several previous studies have shown that SAP variability
increases with disease severity.37–40 This would seem to
contradict our findings of a relatively superior ability of SAP
in detecting progression as disease severity gets worse.
However, it is important to note that such relationship
between disease severity and SAP variability is valid for
measurements expressed in the decibel scale. Even though
variability in decibels increases with worsening visual field
damage, due to the logarithmic scaling, a 1-dB change in later
stages of the disease corresponds to a much smaller change in
terms of neural loss or structural damage than a 1-dB change in
early disease.11,41,42 Therefore, even relatively small losses of
neural tissue in later stages of the disease may produce
relatively large changes in visual sensitivity as measured in
decibels, overcoming at least in part the limitation of increased
variability and making detection of change in decibels relatively
easier.10
FIGURE 2. Example of an eye of a glaucoma patient with glaucomatous optic neuropathy but normal visual field at baseline (mild disease).
Significant progression was seen on SD-OCT RNFL thickness measurements over time, with a rate of change of2.28 lm/y (P¼ 0.001). Progression
was not seen on SAP mean sensitivity measurements over time, with a slope of 0.25 dB/y (P¼ 0.188).
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As expected, the number of tests (visits) acquired during
follow-up also significantly influenced the ability to detect
change. It is expected that a greater number of visits will make
detection of change easier for both structural and functional
tests. However, we also found a significant interaction between
baseline disease severity and number of tests in explaining the
relative odds of detecting change by SD-OCT versus SAP. This is
illustrated by Figure 1 and also by the analysis of the raw data
presented in Table 2. When only a small number of tests were
available during follow-up (less than eight), detection of
progression was more common for SD-OCT than SAP for all
stages of the disease, even in eyes with moderate and advanced
damage. Conversely, when a large number of tests were
available (>12 tests), the odds of detecting change were higher
for SAP compared with SD-OCT for eyes with moderate and
advanced disease at baseline.
Our findings may be important in providing clinicians with
information that can be used to tailor the frequency and type of
test according to the stage of disease. However, such test
customization strategy might be difficult to implement in
clinical practice, as there are no clear cutoffs of when to
perform one test versus the other. Additionally, even though
under certain circumstances the relative odds of detecting
change may be higher for test A compared with test B, this
does not necessarily imply that all cases of progression will be
detected by test A. Therefore, algorithms that provide a
combination of structural and functional data allowing
effective monitoring throughout the disease continuum might
offer a better solution to this issue.43–48
The present study has limitations. The ability to detect
change was investigated using only trend analysis of global
parameters. This was done to allow equating the specificities
of the tests, an essential requirement for comparing their
abilities to detect change. As there is no current gold standard
for detecting change in glaucoma, our comparison was based
on the relative proportion of glaucoma eyes that were detected
as having statistically significant slopes of progression consid-
ering rates of change that would have only a 5% chance of
occurring in a healthy population. This was done to provide
not only a statistically but also a clinically relevant criteria.
Future studies should, however, investigate the relative ability
to detect change by using other methods such as event-based
detection of localized change or other techniques. As another
limitation of our study, we assumed linear rates of change over
time. Although this assumption is likely to correspond to how
these tests are currently used in clinical practice for relatively
short-term management decisions, it is likely that the true
course of the disease is not linear in the long run. Recent
investigations have also suggested nonlinear models for
investigation of rates of visual field change that might provide
an improvement over current simple linear models.49–52 Future
studies should also investigate this issue.
In conclusion, our results show that the ability to detect
glaucoma progression by SAP and SD-OCT is significantly
influenced by the stage of disease. Our results may provide
useful information for guiding clinicians on the relative utility
of these tests for detecting change throughout the disease
continuum. Furthermore, they may also serve to guide the
FIGURE 3. Example of an eye of a glaucoma patient with moderate disease at baseline (baseline MD deviation of10.96 dB). Significant progression
was seen on SAP with a slope of change in mean sensitivity of 0.51 dB/y (P ¼ 0.009). However, no significant change was seen on SD-OCT
measurements, with a slope of change of 0.02 lm/y (P¼ 0.961).
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construction of indices or strategies combining structural and
functional information for detection of change over time.
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